Tue01312023

Last updateThu, 29 Dec 2022 2pm

Back You are here: Inicio Biology & biomedicine

Patented molecules that counteract the effect of the most common anticoagulant drug

Researchers at IQAC-CSIC have successfully tested molecules that reverse the effect of the anticoagulant heparin, used to treat patients at risk of thrombosis. These new molecules have been patented. Patients treated with heparin may need to block its effect during surgery. The only drug available nowadays has a high molecular weight and may have associated side effects.

Read more ...

Miniaturized device for electrical stimulation of cell cultures

The use of electrical stimulation in medical research is growing rapidly for its effects on cell regeneration. The CSIC, the Autonomous University of Madrid and the University of Florida have developed a miniaturised device for in vitro electrical stimulation of cells and tissues. The technology is available for further development and commercialization.

Read more ...

A new targeted nanosystem improves brain drug delivery for the treatment after a stroke

Direct brain administration through the carotid artery of nanomaterials carrying drugs after a stroke could be an effective method to reduce the undesirable effects in other organs, improving at the same time the arrival of the drug into the brain. A study has tested nanocapsules designed by scientists at the ICMAB-CSIC to transport drug molecules to brain areas by a micro catheter.

Read more ...

DNA probes for the fast detection of SARS-CoV2 and influenza virus

Scientists from the CSIC, the University of Barcelona and the CIBER network laboratory have developed DNA probes for the fast detection of respiratory disease viruses, including SARS-CoV2 and influenza. The technology is available for further development through agreements with industry partners.

Read more ...

A spin-off company will develop a monoclonal antibody to treat autoimmune diseases such as psoriasis

The antibody acts on the immune system to increase anti-inflammatory activity and attenuate inflammation. It will be developed by the Inhibitec Anticuerpos company, created by the scientists who created the technology at the CSIC and the University of Cantabria.

Read more ...